Five months after ending development of its own obesity treatment , Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition.

The COVID-19 vaccine and treatment maker said Monday that it will pay $47.50 in cash for each share of development-stage drugmaker Metsera.

That represents a premium of more than 42% to Metsera’s closing price on Friday. 4

Pfizer also could pay an additional $22.50 per share, depending on how Metsera’s product pipeline develops.

Metsera Inc. has no products on the market, but its pipeline includes four programs in clinical development and one in mid-stage testing. Pfizer said the deal will add expertise and potential oral and injectable treatments.

Pfizer CEO Albert Bourla noted in a statement from the drugmake

See Full Page